Business
Intensity Therapeutics Announces Two Presentations at the Upcoming 2025 San Antonio Breast Cancer Symposium
Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology company focused on the discovery and development of proprietary cancer therapies using its non-covalent, drug-conjugation technology that creates drug products designed to kill tumors and increase immune system recognition of cancers, today announces two presentations at the upcoming 2025 San Antonio Breast Cancer Symposium (SABCS), in San Antonio, TX on December 9-12, 2025.
About this update from Intensity Therapeutics, Inc.
[{"type":"text","content":"SHELTON, Conn., Dec. 4, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology company focused on the discovery and development of proprietary cancer therapies using its non-covalent, drug-conjugation technology that creates drug products designed to kill tumors and increase immune system recognition of cancers, today announces two presentations at the upcoming 2025 San Antonio Breast Cancer Symposium (SABCS), in San Antonio, TX on December 9-12, 2025.","length":554,"tagName":"p"},{"type":"image","alt":"Logo (PRNewsfoto/Intensity Therapeutics Inc.)","displaySize":"","headline":null,"caption":"Logo (PRNewsfoto/Intensity Therapeutics Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":101,"url":"https://media.zenfs.com/en/prnewswire.com/05963c77aa494c20fbf5e997876cf9c8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/zdViy5pzlzPB_LdO71ooeQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE3ODtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/05963c77aa494c20fbf5e997876cf9c8","width":400,"height":101}},"href":"https://mma.prnewswire.com/media/2290007/Intensity_Therapeutics_Inc_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Presentations:","length":14,"tagName":"p"},{"type":"table","headerItems":[],"items":[{"val":[{"colspan":"1","rowspan":"1","style":"PADDING-RIGHT:0.17em;PADDING-LEFT:0.17em;VERTICAL-ALIGN:TOP;TEXT-ALIGN:LEFT;","val":[{"type":"text","content":"Title:","length":6,"tagName":"p","attribs":{}}]},{"colspan":"1","rowspan":"1","style":"PADDING-RIGHT:0.17em;PADDING-LEFT:0.17em;VERTICAL-ALIGN:TOP;TEXT-ALIGN:LEFT;","val":[{"type":"text","content":"Accelerating an Anthracycline-Free Future: A New Drug in Clinical Testing Offers Patients Hope for Safer, More Effective Breast Cancer Therapy Combinations","length":160,"tagName":"p","attribs":{}}]}]},{"val":[{"colspan":"1","rowspan":"1","style":"PADDING-RIGHT:0.17em;PADDING-LEFT:0.17em;VERTICAL-ALIGN:TOP;TEXT-ALIGN:LEFT;","val":[{"type":"text","content":"","length":0,"tagName":"p","attribs":{}}]},{"colspan":"1","rowspan":"1","style":"PADDING-RIGHT:0.17em;PADDING-LEFT:0.17em;VERTICAL-ALIGN:TOP;TEXT-ALIGN:LEFT;","val":[{"type":"text","content":"","length":0,"tagName":"p","attribs":{}}]}]},{"val":[{"colspan":"1","rowspan"...